Having trouble viewing this email? Click here |
![]() |
|
Quick Links
Share with Colleagues ![]() ![]() Credits
Physicians: .25 AMA PRA Category I CreditsTM To Receive Credit In order to receive your certificate of participation, you should read the information about this activity, including the disclosure statements, review the entire activity, take the post-test, and complete the evaluation form. You may then follow the directions to print your certificate of participation. To begin, click the CME icon above. Program Overview Learning Objectives
Upon successful completion of this educational program, the reader should be able to: Faculty Information
Alan Ehrlich, MD Disclosures
Dr. Ehrlich, Dr. Fleming, DynaMed Editorial Team members, and the staff of Antidote Education Company have disclosed that they have no relevant financial relationships or conflicts of interest with commercial interests related directly or indirectly to this educational activity. Accreditation Statements ACCME: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Antidote Education Company and EBSCO Publishing. Antidote is accredited by the ACCME to provide continuing medical education for physicians. Antidote Education Company designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
Last week 512 journal articles were evaluated via DynaMed's Systematic Literature Surveillance and summaries of 183 articles were added to DynaMed content. |
Hydroxychloroquine May Not Improve Symptoms of Primary Sjogren Syndrome in Adults |
|
Sjogren syndrome is a chronic autoimmune disorder characterized by exocrine gland dysfunction resulting in dryness, pain, and fatigue (BMC Med. 2013 Apr 4;11:93 full-text). Hydroxychloroquine is an immunomodulator that is frequently prescribed for patients with primary Sjogren syndrome who present with general symptoms such as fatigue, arthralgia, and myalgia. However, despite its widespread use, clinical data supporting the efficacy of hydroxychloroquine are very limited. A recent randomized trial of 120 adults with primary Sjogren syndrome compared hydroxychloroquine 400 mg orally daily vs. placebo for 24 weeks. Clinical evidence supporting hydroxychloroquine for primary Sjogren syndrome has mostly been confined to small open-label studies. A randomized crossover trial previously failed to demonstrate any symptomatic improvement associated with hydroxychloroquine despite improvements in surrogate markers of disease (Ann Rheum Dis 1993 May;52(5):360 full-text). However, that trial was limited by a very small sample size. The results from this new and much larger trial confirm the previous findings and provide more compelling evidence that hydroxychloroquine does not appear to improve symptoms of primary Sjogren syndrome. Furthermore, use of hydroxychloroquine requires periodic ophthalmologic exams due to a dose-related risk of retinopathy (Ophthalmology 2002 Jul;109(7):1377). |
|
EBSCO Health Launches Pediatric Clinical Information Mobile App PEMSoft Now Available For iPhone, iPad, and Android Devices A mobile app designed specifically for pediatricians, emergency department physicians, physicians-in-training and other medical providers caring for children with acute illnesses and injury, is now available from EBSCO Health, the leading provider of clinical decision support solutions for the healthcare industry. Call for Peer Reviews
We are currently seeking subspecialty reviewers for our Patient Education Resource Center (PERC). PERC provides fact sheets and discharge instructions for patients leaving the hospital or emergency room. These hand-outs fulfill the meaningful use requirements for the Medicare & Medicare Services Incentive Programs. DynaMed Contribution Opportunities
Become a DynaMed Resident Focus Reviewer DynaMed Careers
Looking for a change? The DynaMed editorial team is expanding and looking for talented and driven individuals. Visit the links below to learn about these exciting opportunities. |